{"id":"gsk1024805a","safety":{"commonSideEffects":[{"rate":null,"effect":"Nausea"},{"rate":null,"effect":"Diarrhea"},{"rate":null,"effect":"Abdominal pain"},{"rate":null,"effect":"Headache"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"LPA1 is a G-protein coupled receptor involved in fibrosis, inflammation, and tissue remodeling. By antagonizing LPA1, GSK1024805A inhibits pathological fibrotic signaling cascades. This mechanism is intended to slow or halt progressive fibrotic diseases by reducing myofibroblast activation and extracellular matrix deposition.","oneSentence":"GSK1024805A is a lysophosphatidic acid receptor 1 (LPA1) antagonist that blocks LPA-mediated signaling to reduce fibrotic and inflammatory responses.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:14:39.139Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Idiopathic pulmonary fibrosis (IPF)"}]},"trialDetails":[{"nctId":"NCT00624819","phase":"PHASE3","title":"Assessment of Antibody Persistence in Children Previously Vaccinated With Pneumococcal Conjugate Vaccine","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2008-03-03","conditions":"Infections, Streptococcal, Streptococcus Pneumoniae Vaccines","enrollment":524}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Synflorix"],"phase":"phase_3","status":"active","brandName":"GSK1024805A","genericName":"GSK1024805A","companyName":"GlaxoSmithKline","companyId":"glaxosmithkline","modality":"Biologic","firstApprovalDate":"","aiSummary":"GSK1024805A is a lysophosphatidic acid receptor 1 (LPA1) antagonist that blocks LPA-mediated signaling to reduce fibrotic and inflammatory responses. Used for Idiopathic pulmonary fibrosis (IPF).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":1},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}